Corvus Pharmaceuticals, Inc.
CRVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001626971
No open-market purchases or sales by Corvus Pharmaceuticals, Inc. insiders were filed in the last 90 days; 173 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Corvus Pharmaceuticals, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 57 | 1 | 47 | −9 |
| Shares | 27.4M | 13.8K | 25.6M | −1.78M (−6.5%) |
| Value | $44.9M | $23.0K | $25.4M | −$19.6M (−43.6%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (4)
Institutions that held Corvus Pharmaceuticals, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Securities, LLC | 11,355 | $11.0K | 0.00% |
| BNP Paribas Arbitrage, SA | 1,224 | $1.21K | 0.00% |
| Wells Fargo & Company | 218 | $0 | 0.00% |
| Total Clarity Wealth Management, Inc. | 500 | $0 | 0.00% |
Sold out (13)
Institutions that held Corvus Pharmaceuticals, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Point72 Asset Management, L.P. | 745,000 | $1.22M |
| Ikarian Capital, LLC | 510,126 | $837.0K |
| Pura Vida Investments, LLC | 495,484 | $813.0K |
| Citadel Advisors LLC | 404,545 | $663.0K |
| Susquehanna International Group, LLP | 48,283 | $79.0K |
| Boothbay Fund Management, LLC | 48,211 | $79.0K |
| ExodusPoint Capital Management, LP | 25,563 | $42.0K |
| Coastal Bridge Advisors, LLC | 24,000 | $39.0K |
| Walleye Capital LLC | 15,080 | $25.0K |
| Virtu Financial LLC | 14,269 | $23.0K |
| Cubist Systematic Strategies, LLC | 6,600 | $11.0K |
| US Bancorp | 5,153 | $8.00K |
| Cutler Group LP | 4,700 | $7.00K |
Not filed for Q2 2022 yet (1)
Institutions that held Corvus Pharmaceuticals, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Susquehanna Fundamental Investments, LLC | 13,790 | $23.0K |